Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study

Fig. 2The alternative text for this image may have been generated using AI.

Treatment response and duration of evaluable patients with HER2-positive tumors in the phase Ib and phase II studies. Waterfall plot of the best objective response of patients with HER2-positive GC (a), CRC, and other solid tumors (b); swimming plot of the treatment duration of patients with HER2-positive GC (c), CRC and other solid tumors (d)

Back to article page